Many KRAS-mutant cancer cells have been shown to be sensitive to MEK inhibitors, [35] and KRAS mutations can be detected in up to 30% of lung cancers, dependent upon histology and ethnicity [36-38], suggesting that a subset of lung cancers would likely be highly sensitive to AZD6244. This evidence concerns the gene KRAS and lung carcinoma.